Wu Cong, Xu Qian, Shi Ruizheng, Zhang Guogang
Department of Vasculocardiology, Xiangya Hospital, Central South University, Changsha 410008, China.
Department of Cardiovascular Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019 Oct 28;44(10):1196-1202. doi: 10.11817/j.issn.1672-7347.2019.190326.
The advent of catheter ablation technology has changed the treatment strategy for atrial fibrillation, and the efficacy of catheter ablation is accurate with small surgical trauma. Catheter ablation treatment of atrial fibrillation is significantly better than pharmacologic therapy of anti-arrhythmia and rate control. However, the clinic data of catheter ablation of atrial fibrillation show that the recurrence rate is high. The risk factors for recurrence after catheter ablation include age, sex, body mass index, related primary disease, left atrial volume, pulmonary vein volume, gene, atrial fibrillation types, surgery and so on. Regulation of the above factors is crucial in improving the clinical efficacy and prognosis of catheter ablation of atrial fibrillation.
导管消融技术的出现改变了心房颤动的治疗策略，且导管消融疗效确切，手术创伤小。导管消融治疗心房颤动明显优于抗心律失常和心率控制的药物治疗。然而，心房颤动导管消融的临床数据显示复发率较高。导管消融术后复发的危险因素包括年龄、性别、体重指数、相关基础疾病、左心房容积、肺静脉容积、基因、心房颤动类型、手术等。对上述因素进行调控对于提高心房颤动导管消融的临床疗效及预后至关重要。
